SCHEMBL10276471

SCHEMBL10276471

Cc1ccc(S(=O)(=O)N2CCN(C(CNC(=O)OC(C)(C)C)C(=O)O)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.52
LMNA P02545 4/20 0.48
GAA P10253 3/20 0.48
ADAM17 P78536 1/20 0.48
PKM P14618 3/20 0.47
NPSR1 Q6W5P4 1/20 0.46
ALDH1A1 P00352 4/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
RAB9A P51151 2/20 0.45
STAT1 P42224 2/20 0.45
NPC1 O15118 1/20 0.45
MDM2 Q00987 1/20 0.45
USP2 O75604 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
MAPT P10636 1/20 0.44
TSHR P16473 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1504592 1.00 KDM4E (0.52) KDM4ELMNAGAAADAM17PKM
SCHEMBL1504830 0.91 KDM4E (0.48) KDM4ELMNAGAAADAM17PKM
SCHEMBL1504962 0.82 KDM4E (0.60) KDM4ELMNAGAAPKMNPSR1
SCHEMBL995012 0.81 ADAM17 (0.43) GAAADAM17MEN1KMT2A
SCHEMBL995014 0.81 ADAM17 (0.43) GAAADAM17MEN1KMT2A
SCHEMBL995255 0.81 ADAM17 (0.43) GAAADAM17MEN1KMT2A
SCHEMBL996077 0.81 NPFFR1 (0.43) KDM4ELMNAGAANPSR1ALDH1A1
SCHEMBL996079 0.81 NPFFR1 (0.43) KDM4ELMNAGAANPSR1ALDH1A1
SCHEMBL14244986 0.79 ADAM17 (0.39) GAAADAM17MEN1KMT2A
SCHEMBL995532 0.79 ADAM17 (0.39) GAAADAM17MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9115102-B2 N-[2-hydroxycarbamoyl-2-(piperazinyl) ethyl] benzamide compounds, their preparation and their use as TACE inhibitors GALDERMA RESEARCH & DEVELOPMENT (FR) 2015-08-25 US disclosed
EP-2477968-B1 N-[2-HYDROXYCARBAMOYL-2-(PIPERAZINYL)ETHYL]BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS GALDERMA RES & DEV (FR) 2013-10-23 EP disclosed
US-20120178934-A1 N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178934-A1 N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS CTSB, TPSAB1, PIGS KDM4E 1669/4885LMNA 368/4885GAA 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.